Back

Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk of cardiovascular and renal disease among type 2 diabetes patients in routine care in europe and israel: EMPRISE study results

29 June 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Acute Heart Failure - Epidemiology, Prognosis, Outcome Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2021

About the speaker

Photo
Associate Professor Leo Niskanen

Helsinki University Central Hospital, Helsinki (Finland)

8 More presentations in this session

Presentation thumbnail
Testing for iron deficiency and use of ferric carboxymaltose in patients with heart failure: need for implementation? data from the swedish heart failure registry
Doctor P. Becher (Hamburg, DE)
Abstract Slides Video
Presentation thumbnail
Disparities in follow-up rates after heart failure hospitalisation decreased during the COVID-19 pandemic
Doctor Z. Hughes (Chicago, US)
Abstract Slides Video
Presentation thumbnail
Different renal function patterns in patients with acute heart failure: relationship with outcome and congestion
Associate Professor A. Palazzuoli (Siena, IT)
Abstract Slides Video
Presentation thumbnail
Readmissions in heart failure patients: a portuguese administrative database study from 2008 to 2017
Mrs M. Pardal (Lisboa, PT)
Abstract Slides Video
Presentation thumbnail
No change in predicted risk for in-hospital and one-year mortality in patients hospitalised with heart failure during as compared to before the COVID-19 pandemic
Doctor J. Simkowski (Chicago, US)
Abstract Slides Video

Access the full session

Session thumbnail
Acute Heart Failure - Epidemiology, Prognosis, Outcome

The Event

Event poster

Heart Failure 2021

29 June - 1 July 2021

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources